+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cubicin"

Cubicin - API Insight, 2022 - Product Thumbnail Image

Cubicin - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Cubicin- Drug Insight, 2019 - Product Thumbnail Image

Cubicin- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Cubicin is a brand of immune disorder drugs used to treat a variety of bacterial infections. It is a type of antibiotic known as a lipoglycopeptide, which works by inhibiting the growth of bacteria. Cubicin is used to treat skin and soft tissue infections, as well as complicated intra-abdominal infections. It is also used to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Cubicin is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2004. It is available in both intravenous and intramuscular forms, and is typically administered in a hospital setting. The drug is generally well-tolerated, with few side effects reported. The Cubicin market is highly competitive, with several major pharmaceutical companies offering their own versions of the drug. These include Merck, Pfizer, and AstraZeneca. Other companies, such as Hospira and Teva Pharmaceuticals, also offer generic versions of the drug. Show Less Read more